Emendo was founded in 2015 by Rachel and a group of classmates from Weizmann. Her role at Emendo as Chief Intellectual Property Officer & Head of Pipeline Development includes building is to design an IP strategy for Emendo that both generates an extensive patent portfolio to cover various novel aspects of the technology and products and also navigates the IP space. Additionally, she is building Emendo’s pipeline of clinical programs and the academic and industrial collaborations and partnerships for the pre/clinical development of Emendo’s selected indications and genomic targets.